HUTCHMED (China) (HMDCF) Share-based Compensation (2018 - 2021)
HUTCHMED (China)'s (HMDCF) quarterly Share-based Compensation came in at $5.0 million in Q2 2021, up 87.03% year-over-year from $2.7 million in Q2 2020, and up 68.83% quarter-over-quarter from $2.9 million in Q1 2021.
Analysis
HUTCHMED (China) (HMDCF) Share-based Compensation (2018 - 2021) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Share-based Compensation for 4 consecutive years, with $5.0 million the latest figure, recorded in Q2 2021.
- On a quarterly basis, Share-based Compensation rose 87.03% year-over-year to $5.0 million in Q2 2021; TTM through Jun 2021 was $10.9 million, a 80.62% increase from a year earlier, with the FY2025 full-year figure at $2.5 million, down 18.12% from the prior year.
- Share-based Compensation was $5.0 million for Q2 2021 at HUTCHMED (China), up from $2.9 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $5.0 million in Q2 2021 and troughed at $334000.0 in Q1 2018.
- A 4-year average of $2.2 million and a median of $2.3 million in 2018 frame the typical range for Share-based Compensation.
- Across the five-year window, Share-based Compensation sank 84.97% in 2020 and jumped 754.49% in 2021, its largest moves.
- Over 4 years, Share-based Compensation stood at $2.8 million in 2018, then sank by 36.52% to $1.8 million in 2019, then surged by 51.11% to $2.7 million in 2020, then surged by 87.03% to $5.0 million in 2021.
- The last three Share-based Compensation figures came in at $5.0 million (Q2 2021), $2.9 million (Q1 2021), and $2.7 million (Q2 2020), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.20 Bn | 198.21 Bn | 7.24 Bn | 247.00 Mn |
| 2 | Gilead Sciences | 181.83 Bn | 178.65 Bn | 6.22 Bn | 231.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.47 Bn | 124.61 Bn | 2.84 Bn | 108.10 Mn |
| 4 | Regeneron Pharmaceuticals | 82.56 Bn | 74.56 Bn | 3.93 Bn | 243.00 Mn |
| 5 | Argenx Se | 61.59 Bn | 56.40 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.65 Bn | 49.51 Bn | 52.00 Mn | 120.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Biogen | 31.42 Bn | 30.13 Bn | 1.96 Bn | 77.40 Mn |
| 9 | Roivant Sciences | 30.21 Bn | 30.21 Bn | 1.16 Mn | 83.34 Mn |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2021 | 4.98 Mn |
| Mar 31, 2021 | 2.95 Mn |
| Jun 30, 2020 | 2.66 Mn |
| Mar 31, 2020 | 345,000.00 |
| Dec 31, 2019 | 1.76 Mn |
| Sep 30, 2019 | 1.29 Mn |
| Jun 30, 2019 | 1.83 Mn |
| Mar 31, 2019 | 2.30 Mn |
| Dec 31, 2018 | 2.77 Mn |
| Sep 30, 2018 | 2.34 Mn |
| Jun 30, 2018 | 2.46 Mn |
| Mar 31, 2018 | 334,000.00 |